Zentalis Pharmaceuticals, Inc.
General ticker "ZNTL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $153.1M (TTM average)
Zentalis Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 45.8%.
Estimated limits based on current volatility of 4.2%: low 4.55$, high 4.95$
Factors to consider:
- Total employees count: 106 (-36.1%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: No approved products, Limited operating history, Net losses, Need for additional capital, Product approval failure
- Current price 63.7% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.11$, 3.12$]
- 2026-12-31 to 2027-12-31 estimated range: [1.09$, 3.04$]
Financial Metrics affecting the ZNTL estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 133.78 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 74.82 > 64.23
- Negative: negative Net income
Short-term ZNTL quotes
Long-term ZNTL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $67.42MM | $0.00MM |
| Operating Expenses | $299.51MM | $258.62MM | $152.81MM |
| Operating Income | $-299.51MM | $-191.19MM | $-152.81MM |
| Non-Operating Income | $22.62MM | $25.50MM | $16.19MM |
| R&D Expense | $189.59MM | $167.77MM | $107.30MM |
| Income(Loss) | $-276.89MM | $-165.69MM | $-136.62MM |
| Taxes | $-0.60MM | $0.18MM | $0.44MM |
| Other Income(Loss) | $-16.01MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-292.19MM | $-165.84MM | $-137.06MM |
| Stockholders Equity | $437.28MM | $337.19MM | $216.20MM |
| Assets | $551.69MM | $430.34MM | $288.97MM |
| Operating Cash Flow | $-207.82MM | $-170.86MM | $-125.25MM |
| Capital expenditure | $0.58MM | $0.22MM | $0.00MM |
| Investing Cash Flow | $-44.46MM | $176.56MM | $131.62MM |
| Financing Cash Flow | $237.30MM | $0.11MM | $-4.28MM |
| Earnings Per Share** | $-4.47 | $-2.33 | $-1.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.